Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Biophytis SA (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
BPTS
Nasdaq
8731
https://www.biophytis.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Biophytis SA (ADR)
Biophytis Announces Receipt of Nasdaq Notice
- Nov 17th, 2023 10:15 pm
Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos (BIO101) in Brazil
- Oct 30th, 2023 5:20 am
Biophytis Receives Notice of Delisting From NASDAQ and Announces It Will Request a Hearing Before the NASDAQ Hearings Panel
- Oct 27th, 2023 9:15 pm
Biophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its Operations
- Sep 27th, 2023 9:45 pm
Biophytis (BPTS) Soars 73% on Partnership With Skyepharma
- Sep 26th, 2023 11:32 am
Biophytis shares surge 73% following partnership deal with Skyepharma
- Sep 25th, 2023 4:09 pm
Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)
- Sep 25th, 2023 5:30 am
Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19
- Sep 19th, 2023 5:40 am
Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer
- Sep 14th, 2023 5:30 am
Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia
- Sep 11th, 2023 5:20 am
Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York
- Sep 4th, 2023 9:30 pm
Biophytis Announces Next Regulatory Steps in Europe and the United States for its COVA Project
- Aug 16th, 2023 5:15 am
Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe
- Aug 8th, 2023 5:20 am
Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19
- Jul 20th, 2023 5:20 am
Biophytis Announces $3.8 Million Registered Direct Offering
- Jul 19th, 2023 6:20 am
Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound
- Jul 18th, 2023 5:20 am
Biophytis Has Filed with The FDA For Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia
- Jul 10th, 2023 5:00 am
Biophytis Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress
- Jun 19th, 2023 5:30 am
Biophytis: Results of the Annual General Meeting on June 16, 2023 All Resolutions Presented by the Company Have Been Adopted
- Jun 16th, 2023 9:20 pm
Biophytis to Participate at the BIO International Convention in Boston from the 5th to the 8th of June
- Jun 5th, 2023 6:20 am
Scroll